venerdì, 16 ottobre 2026

Notizie AIOM – anno XVI n. 697

5 Novembre 2018

National Survey Reveals Surprising Number of Americans Believe Alternative Therapies Can Cure Cancer

October 30, 2018 - Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology (ASCO)’s second annual National Cancer Opinion Survey. This is despite research showing that patients ...
Leggi tutto

5 Novembre 2018

IASLC Issues Statement on Lung Cancer Screening With Low-Dose Computed Tomography

October 30, 2018 - The International Association for the Study of Lung Cancer (IASLC) recently issued a statement on lung cancer screening with low-dose computed tomography (CT) based on the results of the Dutch-Belgian NELSON lung cancer screening trial presented at the ...
Leggi tutto

5 Novembre 2018

New ASTRO/ASCO/AUA Guideline for Early-Stage Prostate Cancer Supports Use of Hypofractionated Radiotherapy

November 1, 2018 - Three prominent medical societies have issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external-beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient ...
Leggi tutto

5 Novembre 2018

FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

October 30, 2018 - The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). The approval is based on results ...
Leggi tutto

5 Novembre 2018

FDA Approves Lorlatinib for ALK+ NSCLC

November 2, 2018 - The FDA has granted lorlatinib an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs). Specifically, lorlatinib ...
Leggi tutto

5 Novembre 2018

Working with stakeholders to improve availability of medicines in the EU

October 31, 2018 - The task force set up by EMA and the Heads of Medicines Agencies (HMA) on availability of authorised human and veterinary medicines is organising a two-day workshop (8-9 November 2018) at EMA in London to gather stakeholders' perspectives on how to better ...
Leggi tutto

5 Novembre 2018

Meeting highlights from EMA’s safety committee (PRAC) 29-31 October 2018

October 31, 2018 - At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of signals, risk management plans, periodic safety update reports ...
Leggi tutto

5 Novembre 2018

Venetoclax/Rituximab Combo Approved in Europe for CLL

November 1, 2018 - The European Commission has approved venetoclax for use in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. The approval was based on findings from ...
Leggi tutto

5 Novembre 2018

Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study

To investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer. Prospective, nationwide cohort study. Denmark, ...
Leggi tutto

5 Novembre 2018

Reporting harms more transparently in trials of cancer drugs

Studies of cancer drugs often use terms that downplay the seriousness of adverse events. Bishal Gyawali and colleagues call for greater clarity and transparency. The clinical trial report of ribociclib, a drug for breast cancer, mentions in its discussion that “Most ...
Leggi tutto